Skip to main content

Advertisement

SpringerLink
Log in

Potential of Antineoplastons in Diseases of Old Age

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Burzynski S. Investigations on unknown ninhydrin-reacting substances in human blood serum I. Attempts at identification of three such substances. Experientia 1969; 25: 490–1

    PubMed  CAS  Google Scholar 

  2. Burzynski SR. Antineoplastons — history of the research (I). Drug Exp Clin Res 1986; 12: 1–9

    CAS  Google Scholar 

  3. Burzynski SR. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. Physiol Chem Phys 1973; 5: 437–47

    PubMed  CAS  Google Scholar 

  4. Burzynski SR, Loo TL, Ho DH, et al. Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. Physiol Chem Phys 1976; 8: 13–22

    PubMed  CAS  Google Scholar 

  5. Gross S, Galicka N, Grabarczyk M, et al. Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. Clin Chem 1977; 23: 148–9

    PubMed  CAS  Google Scholar 

  6. Beall P, Szopa B, Burzynski SR, et al. Polypeptides that inhibit human breast cancer division. Cancer Biochem Biophys 1979; 3: 93–6

    PubMed  CAS  Google Scholar 

  7. Burzynski SR. Antineoplastons: biochemical defense against cancer. Physiol Chem Phys 1976; 8: 275–9

    PubMed  CAS  Google Scholar 

  8. Burzynski SR. Isolation, purification and synthesis of antineoplastons. Int J Exp Clin Chemother 1989; 2: 63–9

    CAS  Google Scholar 

  9. Burzynski SR. Novel differentiation inducers. In: Adam D, editor. Recent Advances in Chemotherapy. Munich: Futuramed Publishers, 1992

    Google Scholar 

  10. Burzynski SR. Synthetic antineoplastons and analogs. Drugs Future 1986; 11: 679–88

    Google Scholar 

  11. Burzynski SR. Immunosurveillance versus chemosurveillance. Postepy Nauk Medycznych 1993; 6: 260–2

    Google Scholar 

  12. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990; 16: 361–9

    PubMed  CAS  Google Scholar 

  13. Burzynski SR, Hendry LB, Mohabbat MO, et al. Purification, structure determination, synthesis and animal toxicity studies of antineoplaston A10. Proceedings of the Thirteenth International Congress on Chemotherapy: 1983 Aug 28–Sep 2; Vienna

  14. Ashraf AQ, Liau MC, Mohabbat MO, et al. Preclinical studies of antineoplaston A10 injections. Drugs Exp Clin Res 1986; 12 Suppl. 1: 37–45

    PubMed  CAS  Google Scholar 

  15. Burzynski SR, Mohabbat MO, Lee SS. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exp Clin Res 1986; 12 Suppl. 1: 11–6

    PubMed  CAS  Google Scholar 

  16. Zetterberg A, Engstrom W. Glutamine and the regulation of DNA replication and cell multiplication in fibroblasts. J Cell Physiol 1981; 108: 365–73

    PubMed  CAS  Google Scholar 

  17. Szkudlinski M, Lewinski A, Rybicka I, et al. Glutamine derivatives as novel anticancer agents acting via gastrin binding sites. Med Hypotheses 1990; 32: 85–8

    PubMed  CAS  Google Scholar 

  18. Turowski GA, Rashid Z, Hong F, et al. Glutamine modulates phenotype and stimulates proliferation in human colon cancer cell lines. Cancer Res 1994; 54: 5974–80

    PubMed  CAS  Google Scholar 

  19. Burzynski SR. Phase I clinical studies of antineoplaston AS2-5 injections. In: Ishigami J, editor. Recent advances in chemotherapy. Tokyo: University of Tokyo Press, 1985

    Google Scholar 

  20. Lehner AF, Burzynski SR, Hendry LB. 3-phenylacetylamino-2,6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. Drugs Exp Clin Res 1986; 12 Suppl. 1: 57–72

    PubMed  CAS  Google Scholar 

  21. Hendry LB, Muldoon TG, Burzynski SR, et al. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exp Clin Res 1987; 13 Suppl. 1: 77–81

    PubMed  CAS  Google Scholar 

  22. Hendry LB, Muldoon TG, Burzynski SR. Modeling studies suggest the modified dipeptide analog phenylacetylamino-2,6-piperidinedione may interact with DNA. Adv Exp Clin Chemother 1988; 2: 11–3

    Google Scholar 

  23. Michalska D. Theoretical investigations on the structure and potential binding sites of antineoplaston A10 and experimental findings. Drugs Exp Clin Res 1990; 16: 342–9

    Google Scholar 

  24. Michalska D. MNDO studies on the structure of antineoplaston A10, glutarimide and piperidine. J Mol Structure 1991; 231: 357–66

    Google Scholar 

  25. Hendry LB, Chu CK, Huang JC, et al. Structure-activity relationships, molecular modeling and antitumor activity of phenylacetylamino-2,6-piperidinediones. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991

    Google Scholar 

  26. Liau MC, Burzynski SR. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res 1986; 12 Suppl. 1: 77–86

    PubMed  CAS  Google Scholar 

  27. Liau MC, Lee SS, Burzynski SR. Modulation of cancer methylation complex isozymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. Int J Tissue React 1990; 12 Suppl.: 27–36

    Google Scholar 

  28. Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Int J Exp Clin Chemother 1992; 5: 9–17

    Google Scholar 

  29. Holliday R. The inheritance of epigenetic defects. Science 1987; 238: 163–70

    PubMed  CAS  Google Scholar 

  30. Charache S, Dover G, Smith K, et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the β-γ-δ-globin gene complex. Proc Natl Acad Sci USA 1983; 80: 4842–6

    PubMed  CAS  Google Scholar 

  31. Reik W. Genomic imprinting and genetic disorders in man. Trends Genet 1989; 5: 331–6

    PubMed  CAS  Google Scholar 

  32. Ferguson-Smith AC, Reik W, Surani MA. Genomic imprinting and cancer. Cancer Surv 1990; 9: 487–503

    PubMed  CAS  Google Scholar 

  33. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733–7

    PubMed  CAS  Google Scholar 

  34. Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Int J Exp Clin Chemother 1989; 2: 187–99

    Google Scholar 

  35. Liau MC, Luong Y, Liau CP, et al. Prevention of drug-induced DNA hypermethylation by antineoplastons. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1992

    Google Scholar 

  36. Dover G, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Eng J Med 1992; 327: 569–70

    CAS  Google Scholar 

  37. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987; 13 Suppl. 1: 17–29

    PubMed  Google Scholar 

  38. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of oral formulation of antineoplaston A3. Tenth International Congress on Pharmacology: 1987 Aug 23–28; Sydney

  39. Burzynski SR. Methods for treating neurofibromatosis. US Patent No. 5391575

  40. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993; 73: 611–20

    PubMed  CAS  Google Scholar 

  41. Lupu R, Colomer R, Zugmaier G, et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 1990; 249: 1552–5

    PubMed  CAS  Google Scholar 

  42. Wen D, Peles E, Cupples R, et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992; 69: 559–72

    PubMed  CAS  Google Scholar 

  43. Gale NW, Kaplan S, Lowenstein EJ, et al. Grb2 mediates EGF-c dependent activation of guanine nucleotide exchange on Ras. Nature 1993; 363: 88–92

    PubMed  CAS  Google Scholar 

  44. Chardin P, Camonis JH, Gale N, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993; 260: 1338–43

    PubMed  CAS  Google Scholar 

  45. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993; 363: 83–5

    PubMed  CAS  Google Scholar 

  46. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–30

    PubMed  CAS  Google Scholar 

  47. Diekmann D, Brill S, Garett MD, et al. Bcr encodes a GTPase activating protein for p21ras. Nature 1991; 351: 400–2

    PubMed  CAS  Google Scholar 

  48. Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role in p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993; 82: 1838–47

    PubMed  CAS  Google Scholar 

  49. Khosvari-Far R, Cox AD, Kato K, et al. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ 1992; 3: 461–9

    Google Scholar 

  50. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993; 260: 1937–42

    PubMed  CAS  Google Scholar 

  51. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934–7

    PubMed  CAS  Google Scholar 

  52. Bonner TI, Kerby SB, Sutrave P, et al. Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 1985; 5: 1400–7

    PubMed  CAS  Google Scholar 

  53. Stokoe D, Macdonald SG, Cadwallader K, et al. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994; 264: 1463–7

    PubMed  CAS  Google Scholar 

  54. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994; 369: 411–4

    PubMed  CAS  Google Scholar 

  55. Greenblatt MS, Bennett WP, Hollstein BM, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–78

    PubMed  CAS  Google Scholar 

  56. Barlow DP. Methylation and imprinting: from host defense to gene regulation. Science 1993; 260: 309–10

    PubMed  CAS  Google Scholar 

  57. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821–8

    PubMed  CAS  Google Scholar 

  58. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857–60

    PubMed  CAS  Google Scholar 

  59. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment Hodgkin’s disease. J Natl Cancer Inst 1993; 85: 25–31

    PubMed  CAS  Google Scholar 

  60. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413–7

    PubMed  CAS  Google Scholar 

  61. Thut CJ, Chen JL, Klemm R, et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995; 267: 100–4

    PubMed  CAS  Google Scholar 

  62. Wang CY, Petryniak B, Thompson CB, et al. Regulation of the Ets-related transcription Factor Elf-1 by binding to the retinoblastoma protein. Science 1993; 260: 1330–5

    PubMed  CAS  Google Scholar 

  63. Hendry LB, Muldoon TG. Actions of an endogenous antitumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA. J Steroid Biochem 1988; 30: 325–8

    PubMed  CAS  Google Scholar 

  64. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–36

    PubMed  CAS  Google Scholar 

  65. Liang XH, Volkmann M, Klein R, et al. Co-localization of the tumor-suppressor protein p53 and human papilloma-virus E6 protein in human cervical carcinoma cell lines. Oncogene 1993; 8: 2645–52

    PubMed  CAS  Google Scholar 

  66. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265: 391–4

    PubMed  CAS  Google Scholar 

  67. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973; 70: 1753–6

    PubMed  CAS  Google Scholar 

  68. Ballester R, Marchuk, D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990; 63: 851–9

    PubMed  CAS  Google Scholar 

  69. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990; 63: 843–9

    PubMed  CAS  Google Scholar 

  70. Bandara LR, Adamczewski JP, Hunt T, et al. Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 1991; 352: 249–51

    PubMed  CAS  Google Scholar 

  71. Mannevik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci USA 1985; 82: 7202–6

    Google Scholar 

  72. Meyer DJ, Coles B, Pemble SE, et al. Theta, a new class of glutathione transferases purified from rat and man. Biochem J 1991; 274: 409–14

    PubMed  CAS  Google Scholar 

  73. Nazar-Stewart V, Motulsky AG, Eaton DL, et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993; 53: 2313–8

    PubMed  CAS  Google Scholar 

  74. Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1 ) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85: 1159–64

    PubMed  CAS  Google Scholar 

  75. Lafuente A, Pujol F, Caretero P, et al. Human glutathione Stransferase mu (GSTµ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett 1993; 68: 49–54

    PubMed  CAS  Google Scholar 

  76. Fryer AA, Zhao L, Alldersea J, et al. The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. Carcinogenesis 1993; 14: 563–6

    PubMed  CAS  Google Scholar 

  77. Burzynski SR. Treatment of bladder cancer with antineoplaston formulations. Adv Exp Clin Chemother 1988; 2: 37–46

    Google Scholar 

  78. Lee SS, Mohabbat MO, Burzynski SR. Tissue culture and acute animal toxicity studies of antineoplaston A2. Future Trends Chemother 1985; 6: 481–4

    Google Scholar 

  79. Lee SS, Mohabbat MO, Burzynski SR. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exp Clin Res 1987; 13 Suppl. 1: 13–6

    PubMed  CAS  Google Scholar 

  80. Lee SS, Burzynski SR. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exp Clin Res 1987; 13 Suppl. 1: 31–5

    PubMed  Google Scholar 

  81. Khalid M, Burzynski SR. N,N’ disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs Exp Clin Res 1987; 13 Suppl. 1: 57–60

    PubMed  CAS  Google Scholar 

  82. Muldoon TG, Copland JA, Lehner AF, et al. Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10. Drugs Exp Clin Res 1987; 13 Suppl. 1: 83–8

    PubMed  Google Scholar 

  83. Muldoon TG, Copland JA, Hendry LB. Actions of antineoplaston A10 on the genesis and maintenance of specific sub-population of rodent mammary tumor cells. Adv Exp Clin Chemother 1988; 2: 15–8

    Google Scholar 

  84. Liau MC, Lee SS, Burzynski SR. Differentiation inducing components of antineoplaston A5. Adv Exp Clin Chemother 1988; 6: 19–25

    Google Scholar 

  85. Lee SS, Burzynski SR. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. Adv Exp Clin Chemother 1988; 6: 27–31

    Google Scholar 

  86. Xu W, Yu R, Gao C, et al. The preliminary antitumor assay of antineoplaston A10 against the S180 and the effects on cAMP levels in tumor and liver tissues of mice. Adv Exp Clin Chemother 1988; 2: 41–4

    Google Scholar 

  87. Hendry LB, Muldoon TG. Actions of an endogenous antitumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA. J Steroid Biochem 1988; 30: 325–8

    PubMed  CAS  Google Scholar 

  88. Maruiwa M, Murakami T, Yano H, et al. Antitumor activity of antineoplaston A2, A10 injection on hepatocellular carcinoma cell line and fresh human hepatic tumors. Eighth International Symposium on Future Trends in Chemotherapy: 1988 Mar 28–30; Pisa

  89. Hashimoto K, Koga T, Shintomi Y, et al. The anticancer effect of antineoplaston A10 on human breast cancer serially transplanted to athymic mice. J Jpn Soc Cancer Ther 1990; 25: 1–5

    CAS  Google Scholar 

  90. Liau MC, Lee SS, Burzynski SR. Separation of active anticancer components of antineoplaston A2, A3, and A5. Int J Tissue React 1990; 12 Suppl.: 1–17

    Google Scholar 

  91. Lee SS, Burzynski SR. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. Int J Tiss React 1990; 12 Suppl.: 37–42

    Google Scholar 

  92. Lee SS, Burzynski SR. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. Internat J Exp Clin Chemother 1990; 3: 125–8

    Google Scholar 

  93. Muldoon TG, Copland JA, Hendry LB. Antineoplaston A10 activity on carcinogen-induced rat mammary tumors. Int J Tiss React 1990; 12 Suppl.: 51–5

    Google Scholar 

  94. Silvestro L, Viano I, Bertelli AAE, et al. Biological effects in vitro of A10. Int J Tissue React 1990; 12 Suppl.: 57–60

    Google Scholar 

  95. Tsuda H, Hara H, Eriguchi N, et al. Inhibitory effect of antineoplaston A10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. Kurume Med J 1990;37: 97–104

    PubMed  CAS  Google Scholar 

  96. Wada R, Han G, Moore T, et al. Effects of phenylacetate and its interaction with retinoic acid on human neuroblastoma differentiation. 85th Annual Meeting of the American Association of Cancer Research: 1994 Apr 10–14; San Francisco, 419

  97. Lee SS, Burzynski SR. Antineoplaston A5: a growth inhibitor for cancerous cells and growth stimulator for normal cells. Int J Exp Clin Chemother 1991; 4: 63–5

    Google Scholar 

  98. Nishida H, Yoshida H, Eriguchi N, et al. Inhibitory effect of orally-administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice. J Jpn Soc Cancer Ther 1991; 26: 595–601

    CAS  Google Scholar 

  99. Samid D, Yeh TJ, Shack S. Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFNα activity in vitro. Br J Haematol 1991; 79 Suppl. 1: 81–3

    PubMed  CAS  Google Scholar 

  100. Wood JC, Copland JA, Muldoon TG, et al. 3-Phenylacetylamino-2,6-piperidinedione inhibition of rat Nb2 lymphoma cell mitogenesis. Proc Soc Exp Biol Med 1991; 197: 404–8

    PubMed  CAS  Google Scholar 

  101. Lee SS, Burzynski SR. Synergistic effect of antineoplaston A5 and retinoic acid on the induction of human promyelocytic leukemia cell line HL-60. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1992

    Google Scholar 

  102. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992; 52: 1988–92

    PubMed  CAS  Google Scholar 

  103. Copland JA, Hendry LB, Chu CK, et al. Antiestrogenic effects of 3-phenylacetylamino-2,6-piperidinedione and its parahydroxy analog in MCF-7 (E3) breast tumor cells. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  104. Copland JA, Hendry LB, Chu CK, et al. Inhibition of estrogen stimulated mitogenesis by 3-phenylacetylamino-2, 6-piperidinedione and its para-hydroxy analog. J Steroid Biochem Mol Biol 1993; 46: 451–62

    PubMed  CAS  Google Scholar 

  105. Fukushima K, Kituu T, Miyazaki T, et al. Inhibitory effect of antineoplaston AS2-1 on a human pancreatic cancer cell line. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  106. Samid D, Shack S, Myers CE, et al. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993; 91: 2288–95

    PubMed  CAS  Google Scholar 

  107. Stockhammer G, Johnson R, Lieberman F. Phenylacetate inhibits proliferation of brain tumor derived cell lines in vitro. 84th Annual Meeting of the American Association for Cancer Research: 1993 May 19–22; Orlando, 380

  108. Samid D, Ram Z, Hudgins WR, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994; 54: 891–5

    PubMed  CAS  Google Scholar 

  109. Ram Z, Samid D, Walbridge S, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 1994; 54: 2923–7

    PubMed  CAS  Google Scholar 

  110. Burzynski SR, Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. Drugs Exp Clin Res 1984; 10: 113–8

    Google Scholar 

  111. Burzynski SR, Mohabbat MO. Chronic animal toxicity studies of antineoplaston A2. Drugs Exp Clin Res 1986; 12 Suppl. 1: 73–5

    PubMed  Google Scholar 

  112. Gingold E, Sear CHJ, Smith RN. Mutagenicity studies on antineoplaston A10, AS2-1, and AS2-5 in cultures of Salmonella typhimurium (Ames test). Fifteenth International Congress on Chemotherapy: 1987 July 19–24; Istanbul

  113. Contrera MGD, Casatti L, Lopes RA, et al. Teratogenicity study of antineoplaston A10 injections in rat fetuses. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  114. Ashraf AQ, Liau MC, Kampalath BN, et al. Pharmacokinetic analysis of antineoplaston A10 injections following oral administration in rats. Drugs Exp Clin Res 1987; 13 Suppl. 1: 45–50

    PubMed  CAS  Google Scholar 

  115. Ashraf AQ, Kampalath BN, Burzynski SR. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exp Clin Chemother 1988; 6: 33–9

    Google Scholar 

  116. Wang H, Xu W, Yuan Y. Studies of the release rate and bioavailability of antineoplaston A10 capsule. Drugs Exp Clin Res 1990; 16: 357–9

    PubMed  CAS  Google Scholar 

  117. Xu W, Wang H, Yuan Y. Pharmacokinetic study of radioactive antineoplaston A10 in rats and mice. Drugs Exp Clin Res 1990; 16: 351–5

    PubMed  CAS  Google Scholar 

  118. Sandler M, Ruthven CRJ, Goodwin BL, et al. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. J Neurol Neurosurg Psychiatry 1982; 45: 366–8

    PubMed  CAS  Google Scholar 

  119. Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994; 54: 1690–4

    PubMed  CAS  Google Scholar 

  120. Burzynski SR, Stolzmann Z, Szopa B, et al. Antineoplaston A in cancer therapy (I). Physiol Chem Phys Med NMR 1977; 9: 485–500

    CAS  Google Scholar 

  121. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies of oral formulation of antineoplaston A10. Drugs Exp Clin Res 1984; 10: 891–909

    Google Scholar 

  122. Burzynski SR. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986; 12 Suppl. 1: 17–24

    PubMed  Google Scholar 

  123. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986; 12 Suppl. 1: 25–35

    PubMed  Google Scholar 

  124. Burzynski SR, Kubove E. Toxicology studies of antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986; 12 Suppl. 1: 47–55

    PubMed  Google Scholar 

  125. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. Drugs Exp Clin Res 1987; 13 Suppl. 12: 1–12

    PubMed  Google Scholar 

  126. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987; 13 Suppl. 1: 37–43

    PubMed  Google Scholar 

  127. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of oral formulations of antineoplaston AS2-1. Adv Exp Clin Chemother 1988; 2: 29–36

    Google Scholar 

  128. Thibault A. Experimental therapies — CPB, NCI. 1994; 1–8

  129. Eriguchi N, Tsuda H, Hara H, et al. The effect of antineoplaston A10, AS2-1 on brain tumor. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991

    Google Scholar 

  130. Yoshida H, Nishida H, Kitsuu T, et al. Effect of antineoplastons on multiple brain metastases. J Jpn Soc Cancer Ther 1992; 27: 1943–9

    Google Scholar 

  131. Tsuda H, Sugita Y, Sugita N, et al. Effect of antineoplaston AS2-1 on high grade glioma. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  132. van der Schaar PJ. Antineoplaston therapy in a private out-patient environment. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  133. Burzynski SR. Treatment of malignant brain tumors with antineoplastons. Adv Exp Clin Chemother 1988; 6: 45–56

    Google Scholar 

  134. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1992

    Google Scholar 

  135. Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of antineoplaston A10 and AS2-1 infusions in high grade glioma. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  136. Antineoplastons: request for Phase II trials in CNS malignancies. CTEP Letter: rapid communication request for letters of Intent. Vol. 10: 10, NCI, DCT, CTEP, 1992

  137. Miller RA. Aging and immune function. Int Rev Cytol 1991; 124: 187–215

    PubMed  CAS  Google Scholar 

  138. Zhou D, Chrest FJ, Adler W, et al. Age-related changes in the expression of the TGF-receptor on CD4+ and CD8+ subsets of T-cells. Aging Immunol Infect Dis 1992; 3: 217–26

    Google Scholar 

  139. De Greef GE, Van Staalduinen GJ, Van Doorninck H, et al. Age-related changes of the antigen-specific antibody formation in vitro and PHA-induced T-cell proliferation in individuals who met the health criteria of the Senieur protocol. Mech Ageing Dev 1992; 66: 1–14

    PubMed  Google Scholar 

  140. Saini A, Sei Y. Age-related impairment of early and late events of signal transduction in mouse immune cells. Life Sci 1993; 52: 1759–65

    PubMed  CAS  Google Scholar 

  141. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med 1994; 96: 457–62

    PubMed  CAS  Google Scholar 

  142. Linos A, Worthington JW, O’Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111: 87–98

    PubMed  CAS  Google Scholar 

  143. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis in demographic subsets. Medicine 1985; 64: 285–95

    PubMed  CAS  Google Scholar 

  144. Wallace DJ. Active idiopathic systemic lupus erythematous in a 90 year old woman requiring corticosteroid therapy. J Rheumatol 1991; 18: 1611–2

    PubMed  CAS  Google Scholar 

  145. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983; 304: 177–9

    PubMed  CAS  Google Scholar 

  146. Mathews MB, Reichlin M, Hughes GRV, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984; 160: 420–34

    PubMed  CAS  Google Scholar 

  147. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science 1990; 248: 1380–8

    PubMed  CAS  Google Scholar 

  148. Burzynski SR. Methods for treating autoimmune diseases. U.S. Patent Application No. 07/898295

  149. Gatti RA, Boder E, Vinters HV, et al. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991; 70: 99–117

    PubMed  CAS  Google Scholar 

  150. Waldmann TA, Misiti J, Nelson DL, et al. Ataxia-telangiectasia: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. Ann Intern Med 1983; 99: 367–79

    PubMed  CAS  Google Scholar 

  151. Lin LH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130–2

    PubMed  CAS  Google Scholar 

  152. Hyman C, Hoger M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230–2

    PubMed  CAS  Google Scholar 

  153. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci 1993; 13: 2739–48

    PubMed  CAS  Google Scholar 

  154. Isackson PJ, Murray KD. Neurotrophic factors in the treatment of Alzheimer’s disease. Drug News and Perspectives 1994; 7: 585–92

    Google Scholar 

  155. Olson L. NGF and the treatment of Alzheimer’s disease. Exp Neurol 1993; 124: 5–15

    PubMed  CAS  Google Scholar 

  156. Weiss R. Promising protein for Parkinson’s. Science 1993; 260: 1072–3

    PubMed  CAS  Google Scholar 

  157. Burzynski SR. Methods for treating Parkinson’s disease. US Patent No. 5116622

  158. Juszkiewicz M, Chodkowska A, Burzynski SR, et al. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exp Clin Res 1994; 20: 161–7

    PubMed  CAS  Google Scholar 

  159. Harris JE. The treatment of cancer in an aging population. JAMA 1992; 268: 96–7

    PubMed  CAS  Google Scholar 

  160. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Eng J Med 1995; 332: 143–9

    CAS  Google Scholar 

  161. Weinberg K, Parkmann R. Age, the thymus, and T-lymphocytes. N Eng J Med 1995; 332: 182–3

    CAS  Google Scholar 

  162. Tsuda H, Sugihara S, Nishida H, et al. The characteristics of inhibitory effect of antineoplaston A10 injection on human tumor cells. Ninth International Symposium on Future Trends in Chemotherapy: 1990 Mar 26–28; Geneva

  163. Tsuda H, Sugihara S, Nishida H, et al. The inhibitory effect of the combination of antineoplaston A10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res 1992; 83: 527–31

    PubMed  CAS  Google Scholar 

  164. Simell O, Sipile I, Rajantie J, et al. Waste nitrogen excretion via amino acid acylation: benzoate and phenylacetate. Pediatric Res 1986; 20: 117–24

    Google Scholar 

  165. Kampalath BN, Liau MC, Burzynski B, et al. Chemoprevention by antineoplaston A10 of benzo(a)pyrene induced pulmonary neoplasia. Drugs Exp Clin Res 1987; 13 Suppl. 1: 51–5

    PubMed  Google Scholar 

  166. Eriguchi N, Hara H, Yoshida H, et al. Cheompreventive effect of antineoplaston A10 on urethane-induced pulmonary neoplasm in mice. J Jpn Soc Cancer Ther 1988; 23: 1560–5

    CAS  Google Scholar 

  167. Kampalath BN, Liau MC, Burzynski B, et al. Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin Bl. Int J Tissue React 1990; 12 Suppl.: 43–50

    Google Scholar 

  168. Karp JE, Broder S. Oncology and hematology, Contempo 1994. JAMA 1994; 271: 1693–5

    PubMed  CAS  Google Scholar 

  169. Hewlett IK, Lee SF, Epstein JS. Effects of phenylacetylglutamine and phenylacetic acid on the replication of human immunodeficiency virus in tissue culture. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  170. Burzynski SR, Kubove E, Szymkowski B, et al. Phase II clinical trials of novel differentiation inducer-antineoplaston AS2-1 in AIDS and asymptomatic HIV infection. Eighth International Conference on AIDS/III STD World Congress; 1992 Jul 19–24; Amsterdam

  171. Kulczycki J, Sobczyk W, Iwinska B, et al. Application of antineoplaston AS2-1 in the therapy of subacute sclerosing panencephalitis. Preliminary report. Eighteenth International Congress on Chemotherapy: 1993 Jun 27–Jul 2; Stockholm

  172. Burzynski SR. Methods for treating AIDS. US Patent Nos. 5089508; 5254587

  173. Burzynski SR. Methods for treating viral infections. US Patent No. 5244922

  174. Li CJ, Friedman DJ, Wang C, et al. Induction of apoptosis in unifected lymphocytes by HIV-1 tat protein. Science 1995; 268: 429–31

    PubMed  CAS  Google Scholar 

  175. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298–300

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Burzynski Research Institute, Inc., 12000 Richmond Avenue, Houston, Texas o[77082, USA

    Stanislaw R. Burzynski

Authors
  1. Stanislaw R. Burzynski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burzynski, S.R. Potential of Antineoplastons in Diseases of Old Age. Drugs & Aging 7, 157–167 (1995). https://doi.org/10.2165/00002512-199507030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199507030-00001

Keywords

Search

Navigation